JSCPT 2025

Richmond Pharmacology is pleased to confirm our attendance at JSCPT 2025, the Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, taking place in Tokyo from 5th –6th December. Representing Richmond at JSCPT 2025: Dr Jörg Täubel, Chief Executive Officer Dr Ulrike Lorch, Chief Medical Director Stephen Wilkinson, Business Development Manager Nobuo Ittetsu, Head of Japanese Volunteer Recruitment Minoru Takada, Japanese Business Development Executive We look forward to connecting with clinical and regulatory professionals to discuss Richmond’s expertise in: • Early-phase and first-in-human studies • Bridging studies between Europe and Asia • Gene and RNA-based therapy development • Pharmacokinetics, biomarkers, and trial design • Cross-border collaboration in complex trials If you’re attending JSCPT 2025 and seeking a clinical development partner, arrange a meeting with one of our representatives: info@richmondpharmacology.com